About

We exist to restore the body's capacity for health.

Our mission.

Senovia Biosciences is building a new class of pharmaceutical therapies designed to control metabolic state for therapeutic applications.

We believe that many of the most devastating diseases — across neurology, psychiatry, oncology, cardiology, immunology, and infectious disease — share common roots in bioenergetic failure. And we believe that addressing these roots, rather than their downstream consequences, may unlock therapeutic possibilities that have been out of reach.

We are building the platform to make that possible.

Our thesis.

Drug efficacy depends not only on target engagement but on the metabolic state of the tissue receiving the drug. This is not a new observation — it is visible in published data across Alzheimer's, heart failure, immuno-oncology, and epilepsy.

What is new is treating metabolic state as a designable pharmaceutical variable rather than an uncontrollable background condition.

Senovia exists to build the first drugs designed around this principle.

How we work.

→

Speed as a discipline

Every day matters. We optimize for the fastest credible path to patients.

◇

Platform, not assets

We are not building a single drug. We are building a new modality.

◎

Rigor over hype

We let published evidence speak. Every claim on this site is independently verifiable.

⟐

Designed for partnership

From the beginning, we are building for scale — including strategic partnerships with leading pharmaceutical companies.

Leadership.

Joel Anderson

Founder & CEO

Founded Senovia on the thesis that metabolic state is a controllable therapeutic variable with cross-disease applications. Leading platform development across seven therapeutic areas.

For opportunities to work with or join Senovia, please get in touch.